SCHEMBL13401433

SCHEMBL13401433

O=C(O)CCC(=O)Nc1cccc(-c2cn3ccccc3n2)c1

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.77
LMNA P02545 4/20 0.77
MAPT P10636 4/20 0.77
KDM4E B2RXH2 11/20 0.76
SMN1; SMN2 Q16637 8/20 0.76
HPGD P15428 5/20 0.76
RAB9A P51151 4/20 0.76
NPC1 O15118 2/20 0.76
TP53 P04637 2/20 0.76
GFER P55789 2/20 0.76
POLB P06746 4/20 0.71
MAPK1 P28482 2/20 0.62
KMT2A Q03164 2/20 0.61
PTK2B Q14289 1/20 0.56
GLA P06280 1/20 0.56
GAA P10253 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4729920 0.87 ALDH1A1 (1.00) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2
SCHEMBL1494696 0.86 KDM4E (1.00) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2
SCHEMBL25312016 0.85 ALDH1A1 (0.81) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2
SCHEMBL29484580 0.85 ALDH1A1 (0.81) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2
SCHEMBL28933829 0.82 ALDH1A1 (0.78) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2
SCHEMBL1494832 0.77 KDM4E (0.83) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2
SCHEMBL14076569 0.77 KDM4E (0.72) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2
SCHEMBL4727616 0.76 KDM4E (0.82) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2
SCHEMBL4726858 0.76 SMN1; SMN2 (0.78) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2
SCHEMBL1494819 0.76 ALDH1A1 (1.00) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9757375-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-12 US disclosed
US-9757375-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-12 US disclosed
US-20150313898-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-05 US disclosed
US-20150313898-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-05 US disclosed
US-9073896-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2015-07-07 US disclosed
US-9073896-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2015-07-07 US disclosed
US-20140113891-A1 Compounds that inhibit human DNA ligases and methods of treating cancer NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-04-24 US disclosed
US-20140113891-A1 Compounds that inhibit human DNA ligases and methods of treating cancer NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-04-24 US disclosed
US-8445537-B2 Compounds that inhibit human DNA ligases and methods of treating cancer STC.UNM (US) 2013-05-21 US disclosed
US-8445537-B2 Compounds that inhibit human DNA ligases and methods of treating cancer STC.UNM (US) 2013-05-21 US disclosed
US-20100099683-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-22 US disclosed
US-20100099683-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099683-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER LIG1, LIG4, LIG3 ALDH1A1 2436/4885LMNA 785/4885MAPT 3367/4885
US-20150313898-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER LIG1, LIG4, LIG3 ALDH1A1 2436/4885LMNA 785/4885MAPT 3367/4885
US-20140113891-A1 Compounds that inhibit human DNA ligases and methods of treating cancer LIG1, LIG4, LIG3 ALDH1A1 2436/4885LMNA 785/4885MAPT 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.